IP Verse

Dosing Regimen For A Selective S1P1 Receptor Agonist

Patent No. EP3256125 (titled "Dosing Regimen For A Selective S1P1 Receptor Agonist") was filed by Actelion Pharmaceuticals on Dec 10, 2015. The application was issued on Jan 26, 2022.

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
STADA ARZNEIMITTELOct 26, 2022HAMM & WITTKOPP
TEVA PHARMACEUTICALSOct 21, 2022ELKINGTON AND FIFE

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP3256125

ACTELION PHARMACEUTICALS
Application Number
EP15807916A
Filing Date
Dec 10, 2015
Status
Granted And Under Opposition
Dec 24, 2021
Publication Date
Jan 26, 2022
External Links
Slate, Register , Google Patents